- The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
Viking Therapeutics' GLP-1 results are showing how they stack up against the market leaders, Novo Nordisk and Eli Lilly.
1 report, 1 independent
Updated Sep 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Viking Therapeutics' GLP-1 results are showing how they stack up against the market leaders, Novo Nordisk and Eli Lilly.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Viking Therapeutics
company in San Diego, United States
Nothing else this week.
-
Novo Nordisk
Danish pharmaceutical company
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Clue and Novo Nordisk have partnered to provide health services.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- Michael Yee provided stock views on Novo Nordisk and Eli Lilly on October 8, 2026.
- Hanmi Pharmaceutical won approval for its homegrown GLP-1 obesity drug, while Eli Lilly expands its market presence.